Beam Therapeutics Inc. (BEAM) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $100.26M; Long-term DebtUSD $100.26M; Long-term Debt, GrossUSD $100.00M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.74M.
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $100.19M; Long-term DebtUSD $100.19M; Long-term Debt, GrossUSD $100.00M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.81M.
Beam Therapeutics Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|
| 2026-06-30 | $100.26M | $100.26M | $100.00M | $3.74M |
| 2026-03-31 | $100.19M | $100.19M | $100.00M | $3.81M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |